

Carolina Saldana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/145122/publications.pdf>

Version: 2024-02-01

16
papers

135
citations

1307594

7
h-index

1281871

11
g-index

16
all docs

16
docs citations

16
times ranked

217
citing authors

#	ARTICLE	IF	CITATIONS
1	CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).. Journal of Clinical Oncology, 2022, 40, 492-492.	1.6	13
2	ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2021, 39, 5046-5046.	1.6	1
3	Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. Cancer Treatment Reviews, 2021, 97, 102191.	7.7	17
4	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. European Journal of Cancer, 2021, 151, 106-114.	2.8	18
5	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19, 554-562.	1.9	6
6	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). European Journal of Cancer, 2021, 158, 1-11.	2.8	4
7	Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy. European Journal of Cancer, 2020, 139, 177-180.	2.8	1
8	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer, 2020, 136, 76-83.	2.8	19
9	Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2020, 38, 490-490.	1.6	0
10	Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.. Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	4
11	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European Journal of Cancer, 2017, 80, 55-62.	2.8	18
12	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 107, 44-53.	4.4	25
13	Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d'Étude des Tumeurs Uro-Génitales) study. European Journal of Cancer, 2015, 51, 1078-1083.	1.6	0
14	Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Channel Group (RCCG) study.. Journal of Clinical Oncology, 2015, 33, 4561-4561.	1.6	1
15	Blood alcohol level in patients treated with gemcitabine and taxanes.. Journal of Clinical Oncology, 2015, 33, e17664-e17664.	1.6	0
16	First line antiangiogenics for advanced renal cell carcinoma: A systematic review and network meta-analysis comparing efficacy and toxicities.. Journal of Clinical Oncology, 2015, 33, e15586-e15586.	1.6	0